174 related articles for article (PubMed ID: 26303327)
1. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.
Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D
Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of anti-tumor activity of Newcastle disease virus by the synergistic effect of cytosine deaminase.
Lv Z; Zhang TY; Yin JC; Wang H; Sun T; Chen LQ; Bai FL; Wu W; Ren GP; Li DS
Asian Pac J Cancer Prev; 2013; 14(12):7489-96. PubMed ID: 24460323
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy.
Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W
J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
5. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J
Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy.
Wu Y; Yan S; Lv Z; Chen L; Geng J; He J; Yu Q; Yin J; Ren G; Li D
Technol Cancer Res Treat; 2014 Apr; 13(2):169-75. PubMed ID: 23819497
[TBL] [Abstract][Full Text] [Related]
7. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas.
Rodriguez-Madoz JR; Zabala M; Alfaro M; Prieto J; Kramer MG; Smerdou C
Hum Gene Ther; 2014 Feb; 25(2):132-43. PubMed ID: 24219025
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.
An Y; Liu T; He J; Wu H; Chen R; Liu Y; Wu Y; Bai Y; Guo X; Zheng Q; Liu C; Yin J; Li D; Ren G
J Biomed Sci; 2016 Jul; 23(1):55. PubMed ID: 27465066
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy.
Sun Y; Wu H; Chen G; Huang X; Shan Y; Shi H; Zhang Q; Zheng Y
Mol Med Rep; 2018 Jan; 17(1):300-306. PubMed ID: 29115604
[TBL] [Abstract][Full Text] [Related]
11. Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses.
Liu T; Zhang Y; Cao Y; Jiang S; Sun R; Yin J; Gao Z; Ren G; Wang Z; Yu Q; Sui G; Sun X; Sun W; Xiao W; Li D
Gene Ther; 2021 Dec; 28(12):697-717. PubMed ID: 32409746
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Activity of a Novel Influenza A Virus Carrying Granulocyte-Macrophage Colony-Stimulating Factor in Hepatocellular Carcinoma.
Penghui Y; Fang S; Ruilan W; Guanglin L; Hongjing G; Yueqiang D; Zhongpeng Z; Xiaolan Y; Zhaohai W; Shaogeng Z; Xiliang W
Hum Gene Ther; 2019 Mar; 30(3):330-338. PubMed ID: 30205709
[TBL] [Abstract][Full Text] [Related]
13. Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect.
Pan Z; He J; Rasoul LM; Liu Y; Che R; Ding Y; Guo X; Yang J; Zou D; Zhang H; Li D; Cao H
PLoS One; 2016; 11(10):e0164723. PubMed ID: 27736965
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy.
Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D
Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
[TBL] [Abstract][Full Text] [Related]
18. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.
Choi IK; Li Y; Oh E; Kim J; Yun CO
PLoS One; 2013; 8(7):e67512. PubMed ID: 23844018
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered bone marrow-derived mesenchymal stem cells co-expressing IFN-γ and IL-10 inhibit hepatocellular carcinoma by modulating MAPK pathway.
Wang H; Wang J; Shi X; Ding Y
J BUON; 2017; 22(6):1517-1524. PubMed ID: 29332347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
